CL2017000329A1 - Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo - Google Patents

Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Info

Publication number
CL2017000329A1
CL2017000329A1 CL2017000329A CL2017000329A CL2017000329A1 CL 2017000329 A1 CL2017000329 A1 CL 2017000329A1 CL 2017000329 A CL2017000329 A CL 2017000329A CL 2017000329 A CL2017000329 A CL 2017000329A CL 2017000329 A1 CL2017000329 A1 CL 2017000329A1
Authority
CL
Chile
Prior art keywords
patients
improve myocardial
myocardial performance
fontan surgery
udenafil
Prior art date
Application number
CL2017000329A
Other languages
English (en)
Inventor
James L Yeager
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of CL2017000329A1 publication Critical patent/CL2017000329A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE GENERALMENTE AL CAMPO DEL USO DE UDENAFILO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO EN PACIENTES QUE SE HAN SOMETIDO A LA OPERACIÓN DE FONTAN.</p>
CL2017000329A 2014-08-12 2017-02-09 Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo CL2017000329A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
CL2017000329A1 true CL2017000329A1 (es) 2017-11-03

Family

ID=55301323

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000329A CL2017000329A1 (es) 2014-08-12 2017-02-09 Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Country Status (24)

Country Link
US (7) US10137128B2 (es)
EP (2) EP3180008B1 (es)
JP (6) JP2017524705A (es)
KR (5) KR20260080519A (es)
CN (2) CN118436655A (es)
AU (3) AU2015302271B2 (es)
BR (1) BR112017002675A2 (es)
CA (5) CA3128697C (es)
CL (1) CL2017000329A1 (es)
CO (1) CO2017000271A2 (es)
DO (1) DOP2017000014A (es)
EA (1) EA201692518A3 (es)
EC (1) ECSP17015154A (es)
IL (2) IL285193B2 (es)
MX (1) MX390977B (es)
MY (1) MY200278A (es)
NZ (1) NZ765800A (es)
PE (1) PE20170469A1 (es)
PH (1) PH12017500120A1 (es)
SG (2) SG10202100300RA (es)
TN (1) TN2017000029A1 (es)
TW (5) TW202118491A (es)
UA (1) UA120514C2 (es)
WO (1) WO2016025100A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390977B (es) * 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo
US20170112857A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
KR102249155B1 (ko) 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
MX2022003593A (es) * 2019-09-24 2022-09-19 Mezzion Pharma Co Ltd Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.
WO2023018972A1 (en) 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions
AU2022419178A1 (en) 2021-12-20 2024-08-08 Mezzion Pharma Co., Ltd. Methods and compositions for improving exercise performance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
CA2623657A1 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2007113243A2 (en) 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
JP2010532319A (ja) 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
DK2512479T3 (en) 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
MX390977B (es) 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Also Published As

Publication number Publication date
DOP2017000014A (es) 2017-06-30
EP3180008A4 (en) 2018-01-24
AU2021202212A1 (en) 2021-05-06
US20230095034A1 (en) 2023-03-30
CA2954183C (en) 2023-10-31
JP2025032254A (ja) 2025-03-11
AU2015302271B2 (en) 2019-02-28
CO2017000271A2 (es) 2017-05-31
CN107073001A (zh) 2017-08-18
US20160045510A1 (en) 2016-02-18
CA2954183A1 (en) 2016-02-18
NZ765796A (en) 2024-02-23
US10137128B2 (en) 2018-11-27
KR20170066334A (ko) 2017-06-14
EA201692518A3 (ru) 2017-11-30
CA3128697A1 (en) 2016-02-18
US20190030038A1 (en) 2019-01-31
JP2024020187A (ja) 2024-02-14
MY200278A (en) 2023-12-18
EP3180008B1 (en) 2023-11-29
TW201617080A (zh) 2016-05-16
CA3128691A1 (en) 2016-02-18
NZ765800A (en) 2024-03-22
JP2019077726A (ja) 2019-05-23
CA3128705C (en) 2025-10-07
IL285193B1 (en) 2023-07-01
SG11201700060WA (en) 2017-02-27
JP2026065149A (ja) 2026-04-14
AU2019203706A1 (en) 2019-06-20
US20180169103A1 (en) 2018-06-21
IL250547B (en) 2021-07-29
KR20210038708A (ko) 2021-04-07
PE20170469A1 (es) 2017-04-21
CA3128697C (en) 2025-10-07
WO2016025100A2 (en) 2016-02-18
TW202002982A (zh) 2020-01-16
EP3180008A2 (en) 2017-06-21
MX2017001396A (es) 2017-12-04
MX390977B (es) 2025-03-21
TN2017000029A1 (en) 2018-07-04
KR20230116098A (ko) 2023-08-03
SG10202100300RA (en) 2021-02-25
CA3128680A1 (en) 2016-02-18
TW202224685A (zh) 2022-07-01
TW202400176A (zh) 2024-01-01
CA3128680C (en) 2025-10-07
AU2015302271A1 (en) 2017-01-12
US12048701B2 (en) 2024-07-30
EP4342531A3 (en) 2024-06-26
TWI767153B (zh) 2022-06-11
TW202118491A (zh) 2021-05-16
IL250547A0 (en) 2017-03-30
UA120514C2 (uk) 2019-12-26
TWI730944B (zh) 2021-06-21
ECSP17015154A (es) 2017-05-31
KR20260080519A (ko) 2026-06-02
US20190030037A1 (en) 2019-01-31
US10653698B2 (en) 2020-05-19
EA201692518A2 (ru) 2017-07-31
JP2017524705A (ja) 2017-08-31
JP2021091721A (ja) 2021-06-17
CN118436655A (zh) 2024-08-06
CA3128691C (en) 2025-10-07
US20250064817A1 (en) 2025-02-27
EP4342531A2 (en) 2024-03-27
PH12017500120A1 (en) 2017-05-29
CA3128705A1 (en) 2016-02-18
US20220047601A1 (en) 2022-02-17
IL285193A (en) 2021-08-31
TWI860641B (zh) 2024-11-01
BR112017002675A2 (pt) 2017-12-12
IL285193B2 (en) 2023-11-01
KR20240122604A (ko) 2024-08-12

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
MX2017001279A (es) Usos y composiciones de la flagelina.
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CL2018000098A1 (es) Composiciones de plinabulina.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
MX2018007296A (es) Compuestos de isoindol.
ECSP16096831A (es) Derivados de naftiridinadiona
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112017002090A2 (pt) formulação de fator viii
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
CR20150352A (es) Nuevas composiciones antifúngicidas
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.
CL2015002681A1 (es) Formulación de dosificación oral solida del inhibidor de hcv en estado amorfo